MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...

MIT researchers suggests a potential molecular strategy for treating fragile X syndrome by enhancing NMDA subunit function.

Plymouth Meeting’s Harmony Biosciences’ stock fell 10% on Wednesday after the FDA rejected the expansion of its insomnia drug ...

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and ...

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to ...

Mizuho lowered the firm’s price target on Harmony Biosciences (HRMY) to $42 from $52 and keeps an Outperform rating on the shares. The firm ...

According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...

A growth occurring in the next five years will be fuelled by the launch of two high-priced pipeline products providing ...

US-based biopharmaceutical company Spinogenix has published top line outcomes from a Phase II trial of SPG601 for treating ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...